Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE: RDY) on Thursday announced the availability of its antipsychotic medication Fluphenazine Hydrochloride Tablets, USP in the US market.
Fluphenazine Hydrochloride Tablets, USP are a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10 mg, and are approved by the US Food and Drug Administration (FDA).
The Prolixin brand and generic had US sales of approximately USD134m MAT for the 12 months ending in December 2020, according to IQVIA Health.
Fluphenazine is used in the treatment of chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions and hostility.
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Agilent to acquire Proscia for up to USD270m to expand digital pathology capabilities
Bristol Myers Squibb reports positive Phase 3 results for RYZ101 in neuroendocrine tumours
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Lupin Limited receives FDA approval for Phytonadione Injectable Emulsion USP
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder